Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Acquires $37,000.00 in Stock

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher bought 10,000 shares of the company’s stock in a transaction dated Thursday, March 20th. The shares were acquired at an average cost of $3.70 per share, with a total value of $37,000.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $37,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX opened at $3.78 on Wednesday. Amylyx Pharmaceuticals, Inc. has a 12-month low of $1.58 and a 12-month high of $7.27. The firm has a market capitalization of $334.92 million, a P/E ratio of -0.99 and a beta of -0.51. The firm has a 50-day moving average price of $3.53 and a 200 day moving average price of $4.02.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. Equities research analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Amylyx Pharmaceuticals by 41.6% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 880,745 shares of the company’s stock valued at $2,854,000 after buying an additional 258,818 shares during the period. FMR LLC raised its stake in shares of Amylyx Pharmaceuticals by 292.0% in the 3rd quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after acquiring an additional 164,622 shares during the period. Alpha Wave Global LP acquired a new position in shares of Amylyx Pharmaceuticals in the 3rd quarter worth approximately $2,169,000. Walleye Capital LLC boosted its position in shares of Amylyx Pharmaceuticals by 986.5% during the 3rd quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock worth $2,173,000 after purchasing an additional 608,874 shares during the period. Finally, Barclays PLC increased its holdings in Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after purchasing an additional 40,319 shares during the last quarter. 95.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, March 5th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $7.33.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.